ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer.

N. Koyawala,1 J. Silber,2 P. Rosenbaum,1 R. Bloom,1 W. Wang,2 A. Hill,2 S. Nazarian,1 D. Sawinski,1 J. Trofe,1 M. Lim,1 J. Schold,3 P. Reese.1

1University of Pennsylvania, Philadelphia
2The Children's Hospital of Philadelphia, Philadelphia
3Cleveland Clinic, Cleveland.

Meeting: 2016 American Transplant Congress

Abstract number: C35

Keywords: Kidney transplantation

Session Information

Date: Monday, June 13, 2016

Session Name: Poster Session C: Clinical Science - Kidney Immunosuppression: Induction Therapy

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era
  • Age Adapted Immunosuppression for Elderly Kidney Allograft Recipients: Balancing Risks for Cancer versus Rejection.

Induction therapies are commonly used during kidney transplantation (~85% of transplants in 2012). Existing studies of induction therapy are limited by short follow-up and/or absence of information about associated complications including sepsis, lymphoma, and skin cancer. Using linked data from the United Network for Organ Sharing and Centers for Medicare and Medicaid Services, we compared outcomes between 3 induction therapies for recipients transplanted between 1/2003 through 12/2008. We matched recipients based on 15 clinical and demographic characteristics and created 1:1 alemtuzumab-thymoglobulin (6,840 pairs) and alemtuzumab-basiliximab (6,569 pairs) matches, enabling comparisons across all 3 therapies. Primary outcomes were death, death or allograft failure, death or sepsis, and death or lymphoma. Secondary outcomes were death or melanoma and death or non-melanoma skin cancer. Thymoglobulin patients had a lower rate of death or allograft failure relative to alemtuzumab patients (HR = 0.89, p < 0.01). Basiliximab patients had a higher rate of death or sepsis relative to alemtuzumab patients (HR = 1.12, p < 0.01), which may be explained by other factors (e.g., frailty, oral prednisone use) associated with typical alemtuzumab and basiliximab profiles. Differences for other outcomes, like death, were not statistically significant. Survival curves for all 3 therapies suggested outcome differences among induction therapies were not clinically important. Sub-analyses demonstrated modest differences in median costs for care in the first post-transplant year, with alemtuzumab therapy ~$250 cheaper than therapies for matched patients receiving basiliximab or thymoglobulin ($228.60 and $261.70 median differences respectively; p < 0.001). Overall, the modest differences in outcomes across groups suggest, in some cases, factors like convenience and ability to tolerate side effects may be reasonable ways to select induction therapy.

CITATION INFORMATION: Koyawala N, Silber J, Rosenbaum P, Bloom R, Wang W, Hill A, Nazarian S, Sawinski D, Trofe J, Lim M, Schold J, Reese P. Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Koyawala N, Silber J, Rosenbaum P, Bloom R, Wang W, Hill A, Nazarian S, Sawinski D, Trofe J, Lim M, Schold J, Reese P. Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/kidney-transplant-induction-therapies-risks-of-death-allograft-failure-sepsis-and-cancer/. Accessed March 6, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.